

Aus der
Klinik für Neurologie
des Universitätsspitals Zürich
Klinikdirektor: Prof. Dr. Michael Weller

Chances and limitations of antiangiogenic treatment in primary brain tumors

HABILITATIONSSCHRIFT

zur Erlangung der Venia Legendi
der Universität Zürich

verfasst von

Dr. med. Katharina Gertrud Seystahl

Zürich, 18.05.2021

TABLE OF CONTENTS

1. Introduction 5

 1.1. Concept and molecular background of antiangiogenic treatment in primary brain tumors 5

 1.2. Molecular characteristics and classification of diffuse glioma..... 7

 1.3 Evidence for current therapeutic management of patients with diffuse glioma.. 8

 1.4. Classification and evidence for treatment of meningiomas 15

2. Results 20

 Study 1: Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma. 20

 Study 2: Bevacizumab in recurrent WHO grade 2 and WHO grade 3 gliomas... 31

 Study 3: Bevacizumab as an experimental therapeutic option in recurrent WHO grade 2 or WHO grade 3 meningioma..... 37

3. Discussion..... 44

4. Conclusion 52

5. References..... 53

6. Abbreviations 65

7. Declaration of authorship 66

8. Acknowledgments 67

9. Appendix: Original articles of the habilitation..... 68